For the roughly 6.1 million children diagnosed with ADHD in the United States, finding the right medication and dose is often a protracted, subjective process of trial and error. A clinician’s primary tools are periodic check-ins and parent questionnaires, snapshots that can miss the daily reality of a child’s symptoms and side effects. Iluria Health, a digital health startup founded in 2018 in Hod Hasharon, Israel, is betting that the answer to this imprecision is already on millions of wrists. Its software platform analyzes physiological data streams from commercial wearables, aiming to turn heart rate, movement, and heart rate variability into an objective, continuous feedback loop for treatment decisions [Iluria Health].
The Wedge: Remote Patient Monitoring for the Mind
Iluria’s core bet is that remote patient monitoring (RPM), a category well-established for chronic physical conditions like diabetes, can be rigorously applied to neurobehavioral health. The company’s software ingests data from consumer-grade wearables, applying proprietary machine learning algorithms to detect patterns associated with ADHD symptomology and medication response [Iluria Health]. The output is a dashboard for clinicians and families, designed to show whether a prescribed stimulant is having its intended effect on focus and regulation throughout a child’s day, not just during a quiet office visit.
This approach represents a specific technological wedge. Iluria is not developing a new drug, diagnostic device, or therapeutic modality. Instead, it is attempting to build an evidence-based layer of measurement on top of existing treatment pathways. The value proposition hinges on providing what the field often lacks: quantitative, longitudinal data to inform dose titration and medication switches [LinkedIn].
The Founders’ Personal Compass
The company’s direction is deeply informed by the lived experience of its co-founders. CEO Hagay Levy is a father to four children with ADHD and has the condition himself [Xceptional Leaders podcast, August 2026]. Before Iluria, he built a career in Israeli capital markets and business development, bringing a managerial lens rather than a clinical one to the problem [LinkedIn Pulse, January 2023]. Co-founder and Director Birkat Klimshtein Levy, who holds an architecture degree and an MBA, brings over two decades of project management experience and the same personal familiarity as the mother in that family [Iluria Health].
This personal connection is a common narrative in digital health, but it shapes Iluria’s early-stage priorities. The company’s first clinical partnerships and its stated mission to improve quality of life for families reflect a patient-centric orientation from the outset. The leadership is rounded out by VP of Product and Corporate Development Ran Izraeli, who brings early-stage startup and venture capital experience to the team [Iluria Health].
Early Traction and Funding Pathway
Iluria operates at the intersection of clinical validation and early commercialization, a precarious but necessary phase for any medical software. The company reports completing clinical studies with two significant partners: Cincinnati Children’s Hospital Medical Center in the United States and Clalit Health Services, Israel’s largest health maintenance organization, which manages care for approximately five million patients [Iluria Health] [Drooid]. These studies are critical first steps toward generating the peer-reviewed evidence that will be essential for adoption by clinicians and payers.
Financially, Iluria appears to be navigating a phased capital strategy. The company stated in June 2022 that it had secured $850,000 in cumulative dilutive investment from a group including the Dallas-based accelerator Health Wildcatters and the LUMUS Investment Collective, which brought together eight angel investors [Iluria LinkedIn, June 2022]. Public third-party estimates conflict, with some databases showing higher figures, but the company’s own reporting anchors the disclosed amount. Currently, Iluria is publicly seeking $25,000 angel checks, suggesting it is courting a broader base of individual investors for its next increment of growth [Iluria Health].
| Role | Name | Key Background |
|---|---|---|
| Co-Founder & CEO | Hagay Levy | 23+ years in business/finance; personal & family experience with ADHD [Iluria Health][Xceptional Leaders podcast]. |
| Co-Founder & Director | Birkat Klimshtein Levy | 20+ years project/financial management; B.Arch, MBA; mother of children with ADHD [Iluria Health]. |
| VP, Product & Corp. Dev. | Ran Izraeli | Early-stage startup and venture capital experience [Iluria Health]. |
The Road to Clinical Adoption
The path from promising data to standard practice is long and littered with good ideas that failed to scale. For Iluria, the risks are pronounced and familiar to the digital health sector. The most immediate hurdle is the transition from clinical research to commercial deployments. A third-party database note lists "No Customer Deployments" for the company, a common flag for early-stage health tech ventures that have yet to land their first paid enterprise contract [CB Insights].
Furthermore, the company’s scientific claims, while plausible, await the scrutiny of publication. The physiological markers Iluria analyzes,heart rate variability and movement,have documented relationships with arousal and self-regulation, which are core challenges in ADHD. However, proving that algorithmic analysis of this data can reliably guide medication decisions to improve patient outcomes is a higher bar. The company’s recent job postings for a Physician Board Member and a Child and Adolescent Psychiatrist advisor indicate an active effort to bolster its clinical credibility [LinkedIn, December 2025].
- Evidence generation. The four reported clinical studies must yield published results to build trust with the medical community [Hagay Levy / LinkedIn].
- Commercial model. Iluria has identified private mental-health clinics as an initial commercialization target; converting pilot interest into recurring revenue is the next critical test [LinkedIn].
- Regulatory posture. As a clinical decision-support tool, the platform may eventually require a regulatory strategy, though its use of commercial wearables and software-only analysis could place it in a less burdensome category initially.
The company’s most plausible answer to these challenges is its focus on partnerships with large, research-oriented health systems like Cincinnati Children’s and Clalit. Success in these venues can serve as both a validation engine and a reference customer for future sales.
What Standard Care Looks Like Today
For the millions of children and adolescents managing ADHD, the current standard of care is inherently episodic. Treatment typically involves stimulant medications like methylphenidate or amphetamines, prescribed by a pediatrician or psychiatrist. Dosing is adjusted over weeks or months based on brief office evaluations and subjective reports from parents and teachers about behavior and side effects. This process can stretch for a year or more, a period of instability that impacts a child’s learning and social development. Iluria’s ambition is to collapse that timeline and replace guesswork with data, offering a continuous window into a child’s response that is grounded in their physiology, not just observed behavior. If the company’s technology proves out, the next twelve months will be about moving from research collaboration to a first commercial foothold, turning those angel checks into a validated new tool for a patient population that has long needed one.
Sources
- [Iluria Health] Company Website | https://www.iluriahealth.com/
- [LinkedIn] Iluria Health: A New Venture for ADHD Treatment | https://www.linkedin.com/posts/benjamin-davis-smith_iluria-video-june-2023-eng-activity-7209609580681519105-qApq
- [Xceptional Leaders podcast, August 2026] Launching Iluria: Looking in on the Early Stages of a Startup with Hagay Levy | https://podcasts.apple.com/us/podcast/launching-iluria-looking-in-on-the-early-stages/id1435433350?i=1000779695151
- [LinkedIn Pulse, January 2023] Interview with Hagay Levy, CEO and Co-founder of Iluria | https://www.linkedin.com/pulse/people-behind-healthcare-innovation-interview-hagay-levy-gila-tolub
- [Drooid] Clalit Health Services Profile | https://contactout.com/company/Iluria-Health-Ltd-12566
- [Iluria LinkedIn, June 2022] Funding Announcement | https://www.linkedin.com/posts/iluria_httpslnkdindntps-g-so-proud-to-have-activity-6939852889506877440-TD6a
- [CB Insights] Company Profile Note | https://www.cbinsights.com/company/iluria
- [Hagay Levy / LinkedIn] Personal Profile | https://www.linkedin.com/in/hagay-levy-2800605/
- [LinkedIn, December 2025] Physician Board Member Job Posting | https://www.linkedin.com/jobs/view/physician-board-member-at-iluria-4348975760